NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
CYCLOSET (bromocriptine mesylate) by Aurobindo Pharma is mesylate, a sympatholytic, dopamine d2 receptor agonist. Approved for type 2 diabetes mellitus, type 1 diabetes, diabetic ketoacidosis. First approved in 2009.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLOSET is an oral tablet containing bromocriptine mesylate, a dopamine D2 receptor agonist approved in 2009 for type 2 diabetes, type 1 diabetes, and diabetic ketoacidosis. When administered in the morning, it increases insulin sensitivity and glucose disposal while reducing fasting and postprandial hyperglycemia without raising plasma insulin levels. This unique quick-release formulation targets circadian insulin resistance pathways.
$0.003BPart D
Peak5.5 years to LOEAt peak lifecycle with stable but modest Part D spending of $3M and ~3,358 claims in 2023; team size likely small to mid-sized with focus on maintaining niche positioning.
Mechanism of Action
mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without…
Indications (3)
Worked on CYCLOSET at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.